U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783373) titled 'Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia' on Aug. 20.
Brief Summary: This study will evaluate the long-term real-world safety of xanomeline-trospium chloride in adults with schizophrenia receiving routine clinical care in the United States.
Study Start Date: May 01
Study Type: OBSERVATIONAL
Condition:
Schizophrenia
Intervention:
DRUG: xanomeline-trospium chloride
As per product label
DRUG: Oral antipsychotics
As per product label
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services with permission from Health Daily Digest....